


Senkyunolide I

Cat. No.:	HY-N0745
CAS No.:	94596-28-8
Molecular Formula:	C ₁₂ H ₁₆ O ₄
Molecular Weight:	224.25
Target:	Caspase
Pathway:	Apoptosis
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (445.93 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	4.4593 mL	22.2965 mL	44.5931 mL
				5 mM	0.8919 mL	4.4593 mL	8.9186 mL
				10 mM	0.4459 mL	2.2297 mL	4.4593 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (11.15 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (11.15 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (11.15 mM); Clear solution						

BIOLOGICAL ACTIVITY

Description	Senkyunolide I, isolated from <i>Ligusticum chuanxiong</i> Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3 ^{[1][2]} .
-------------	---

REFERENCES

[1]. Wang YH, et al. Effect and mechanism of senkyunolide I as an anti-migraine compound from *Ligusticum chuanxiong*. *J Pharm Pharmacol*. 2011 Feb;63(2):261-6.

[2]. Hu Y, et al. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3. Brain Res. 2015 Apr 24;1605:39-48.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA